NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.91 +0.15 (+1.02 %)
(As of 12/18/2018 12:25 PM ET)
Previous Close$14.76
Today's Range$14.76 - $15.13
52-Week Range$13.51 - $26.98
Volume8,407 shs
Average Volume125,560 shs
Market Capitalization$870.37 million
P/E Ratio-4.48
Dividend YieldN/A
Beta1.19
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DBVT
Previous Symbol
CUSIPN/A
Phone33-1-55-42-78-78

Debt

Debt-to-Equity Ratio0.01
Current Ratio6.60
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-4.48
Forward P/E Ratio-3.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.45 million
Price / Sales63.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.94 per share
Price / Book5.07

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees244
Outstanding Shares57,040,000
Market Cap$870.37 million
OptionableOptionable

DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions

What is DBV TECHNOLOGIE/S's stock symbol?

DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT."

How were DBV TECHNOLOGIE/S's earnings last quarter?

DBV TECHNOLOGIE/S (NASDAQ:DBVT) released its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History.

What price target have analysts set for DBVT?

6 brokerages have issued 1-year price objectives for DBV TECHNOLOGIE/S's shares. Their predictions range from $27.00 to $57.00. On average, they expect DBV TECHNOLOGIE/S's share price to reach $36.40 in the next year. This suggests a possible upside of 144.1% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S.

What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DBV TECHNOLOGIE/S.

Has DBV TECHNOLOGIE/S been receiving favorable news coverage?

News headlines about DBVT stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the stock's share price in the near term.

Who are some of DBV TECHNOLOGIE/S's key competitors?

Who are DBV TECHNOLOGIE/S's key executives?

DBV TECHNOLOGIE/S's management team includes the folowing people:
  • Dr. Pierre-Henri Benhamou, Co-Founder, Chairman & CEO (Age 63)
  • Mr. David Schilansky, Deputy CEO & CFO (Age 43)
  • Dr. Laurent Martin, Chief Devel. Officer (Age 51)
  • Mr. Bertrand Dupont, Co-Founder & CTO (Age 66)
  • Mr. Charles Ruban, Chief Operating Officer (Age 46)

Who are DBV TECHNOLOGIE/S's major shareholders?

DBV TECHNOLOGIE/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (5.28%), Janus Henderson Group PLC (3.87%), Jennison Associates LLC (3.04%), FMR LLC (2.32%), Bank of New York Mellon Corp (0.66%) and BlackRock Inc. (0.55%).

Which institutional investors are selling DBV TECHNOLOGIE/S stock?

DBVT stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Morgan Stanley, Oak Ridge Investments LLC, Daiwa Securities Group Inc. and GW&K Investment Management LLC.

Which institutional investors are buying DBV TECHNOLOGIE/S stock?

DBVT stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Bank of New York Mellon Corp, Bailard Inc., First Midwest Bank Trust Division, Jennison Associates LLC, FMR LLC, Exane Asset Management and BlackRock Inc..

How do I buy shares of DBV TECHNOLOGIE/S?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DBV TECHNOLOGIE/S's stock price today?

One share of DBVT stock can currently be purchased for approximately $14.91.

How big of a company is DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S has a market capitalization of $870.37 million and generates $13.45 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe.

What is DBV TECHNOLOGIE/S's official website?

The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com.

How can I contact DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]


MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: Put Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel